XAIR-Aktie erreicht 52-Wochen-Tief at 0.35 US-Dollar Von Investing.com

In a more aggressive market area, the stock of AIT Therapeutics, while the Kürzel XAIR was traded, has a 52 week price of 0.35 US dollars. The deutliche Rückgang mirrors a knitting trend for the external parts wider, the actions in the process are already fast 85% eingebrochen ist. If you terminate the company, it will become a new business entity in a business environment and its changing branch dynamics. The 52-week critical assessment for AIT Therapeutics, through the external strategies for stabilizing performance and stakeholder interests, improves it.

In others, active nachrichten die Beyond Air more bedeutende Schritte unternommen. Medical and biopharmaceutical medicine has developed the LungFit PH System at the US Naval Hospital Guam, an intensive neonatal treatment with intensive treatment. This venture follows Beyond Airs’ financial financing as it acquires debt of US$17.5 million and clears a new credit hold of US$11.5 million. These maßnahmen sollen de Betrieb des Unternehmens bis Mitte 2026 unterstützen.

Beyond Air reports to a department of the Krankenhausverträge of 60%, one of the best representatives of the US Naval Hospital Guam. The first quarters have found an amount of 0.6 million US dollars, while there is no question of a bet and a bet of 13.5 million US dollars. Proud that Zahlen has seen Beyond Air hit the US dollar in 2025 and now have a value of 10 million US dollars.

Roth/MKM and Piper Sandler analyzers collected their data on Beyond Air. Roth/MKM has set the Aktie von Beyond Air to “Kaufen” and works with the possibilities of LungFit PH-Systems. Piper Sandler has set the price for Beyond Air promotion at US$1.00 due to its “Overweight” rating. These young children underscore the dynamic landscape for Beyond Air.

InvestingPro Acknowledgment

Aktuelle Data von InvestingPro werfen zuätzliches Light on the current situation of AIT Therapeutics (XAIR). The market capitalization of the internal market was a modest US$17.07 million based on a broader mirror of stock markets. Trotz der schwierigen Marktbedingungen said InvestingPro-Tipps, dass

Allerdings Steht das Unternehmen for erheblichen Herausforderungen. An InvestingPro-Tipp knew that the XAIR barmittel was verbrennt, planned to influence its market position and become a besorgniserregengen Factor. Although it still hasn’t happened, the division in the last month is not a profitable war and a negative result of -78.3% on.

On the positive page, analysts have been working for a year, and it is a fact that the net gain of the Unternehmens-steigen is world. These predictions are based on research that could lead to a better understanding of the market immunity we can expect.

If you do any of the following analysis, you can give InvestingPro 13 other tips for XAIR, one of the many financial benefits and market position of our third-party companies.

This description can be performed by the intelligent intelligence. Weitere Informationen entnehmen Sie bitte unseren Nutzungsbedingungen.